Enfusion (ENFN) Set to Announce Earnings on Thursday

Enfusion (NYSE:ENFN) is scheduled to release its earnings data before the market opens on Thursday, May 9th. Analysts expect Enfusion to post earnings of $0.04 per share for the quarter. Enfusion has set its FY 2024 guidance at EPS.Investors interested in listening to the company’s conference call can do so using this link.

Enfusion (NYSE:ENFN) last posted its earnings results on Tuesday, March 12th. The company reported $0.01 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.02). The firm had revenue of $46.49 million during the quarter, compared to analyst estimates of $45.56 million. Enfusion had a net margin of 3.45% and a return on equity of 10.30%. On average, analysts expect Enfusion to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Enfusion Stock Performance

ENFN stock opened at $9.76 on Tuesday. Enfusion has a one year low of $7.37 and a one year high of $11.56. The firm’s fifty day moving average is $9.18 and its 200 day moving average is $9.16. The firm has a market cap of $1.25 billion, a PE ratio of 121.94, a P/E/G ratio of 2.79 and a beta of 0.97.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. The Goldman Sachs Group cut Enfusion from a “neutral” rating to a “sell” rating and dropped their target price for the company from $9.00 to $8.00 in a research report on Wednesday, February 28th. Bank of America boosted their price objective on Enfusion from $8.00 to $9.00 and gave the company an “underperform” rating in a research report on Wednesday, March 13th. Finally, JPMorgan Chase & Co. lowered shares of Enfusion from a “neutral” rating to an “underweight” rating and dropped their target price for the company from $11.00 to $9.00 in a research report on Tuesday, January 30th. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $9.33.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.